Overview

Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Status:
Active, not recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

Prospective, multicenter, phase II trial designed to evaluate whether the addition of Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with mantle cell lymphoma improves the results of the standard R-BAC, in terms of Progression Free Survival.

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione Italiana Linfomi ONLUS

Collaborator:

AbbVie

Treatments:

Bendamustine Hydrochloride
Cytarabine
Rituximab
Venetoclax